In this study on EGFR mutation status, significant findings include that Stage III patients are significantly more likely to exhibit positive EGFR mutations with an odds ratio (OR) of 11.07 (p = 0.021), suggesting advanced cancers are more mutation-prone. This evidence concerns the gene EGFR and cancer.